Rare Pediatric Disease Priority Review Vouchers, Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document issued on: November 17, 2014

First Page		Document Content
Pharmaceutical sciences Orphan drug Priority review voucher FDA Fast Track Development Program New Drug Application Orphan Drug Act Center for Biologics Evaluation and Research Prescription Drug User Fee Act Federal Food Drug and Cosmetic Act Food and Drug Administration Medicine Health		Rare Pediatric Disease Priority Review Vouchers, Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document issued on: November 17, 2014 Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 167,45 KB Share Document on Facebook

	White Paper Consulting Services Supporting Over 50 New Drug Approvals, Labels, and Submissions through Biosimulation DocID: 1aUfl - View Document
	21ST CENTURY CURES DISCUSSION DRAFT Energy and Commerce Committee Chairman Fred Upton (R-MI), Rep. Diana DeGette (D-CO), Health Subcommittee Chairman Joe Pitts (R-PA), Ranking Member Frank Pallone (D-NJ), and Health Subc DocID: 1aj1a - View Document
	21ST CENTURY CURES DISCUSSION DRAFT TITLE I - DISCOVERY SUBTITLE A- NATIONAL INSTITUTES OF HEALTH FUNDING SECTION 1001 – NATIONAL INSTITUTES OF HEALTH REAUTHORIZATION This section would reauthorize the National Institu DocID: 1a7Io - View Document
	Welcome to the STI - SCIH Newsletter! Target patient enrollment number in Phase III Trial of Pafuramidine Maleate (DB289) in Treatment of Sleeping Sickness reached We are very pleased to announce that the targ DocID: 190Uk - View Document
	Dear (Name of your Congressional and Senatorial Official at the Federal Level), I am writing to express interest in the approval status of a bio-drug produced by Genervon Biopharmaceuticals LLS, known as GM604 or GM6 DocID: 173Yp - View Document